XRCC1 and XPD Genetic Polymorphisms Predict Clinical Responses to Platinum-Based Chemotherapy in Epithelial Ovarian Carcinoma

Lianyun WANG,Jieqiang LV,Xueqiong ZHU,Qiusui HUANG,Xiaoming CHEN,Lu XIA,Wenbing CHEN

2013-01-01

Abstract:Objective:To explore the relationship between polymorphisms in XRCCI,XPD and the sensitivity to platinum-based chemotherapy in epithelial ovarian carcinoma(EOC).Methods: Eighty-five subjects who received primary surgery and more than 6 courses of platinum-based combination chemotherapy and the genetic polymorphism of XRCC1,XPD was examined using polymerase chain reaction-restriction fragment length polymorphism analytical method.Results: The relationship between the genotype of XRCC1 Arg399Gln,XPD Lys751Gln and sensitivity of chemotherapy,between chemosensitivity group and resistance group,the difference between XRCC1 Arg399Gln AA,AG,GG and XPD Lys751Gln LL,LG was significant(P0.05).To compare XRCC1 Arg399Gln AA genetype with XRCC1 Arg399Gln AG genetype,the difference was significant(P0.05);To compare XRCC1 Arg399Gln GG genetype with XRCC1 Arg399Gln AG gene type,the chemosensitivity of XRCC1 Arg399GlnGG gene type was 5.31 times(P0.05,95% CI is 1.50-18.84) of XRCC1 Arg399Gln AA gene type.the XRCC1 Arg399GlnLG gene type was 5.44 times(P0.05,95% CI is 1.78-16.65) of XRCC1 Arg399Gln AA gene type.And the chemosensitivity of XPD Lys751Gln LL gene type was 2.88 times of XPD Lys751Gln LGgene type(P0.05,95% CI is 1.11-7.49).Conclusion: Results show that XRCC1 and XPD gene type may be related to platinum-based chemotherapy sensitivity in epithelial ovarian carcinoma.